Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

N. Harmankaya, J. Karlsson, A. Palmquist, M. Halvarsson, Kazuyo Igawa, M. Andersson, P. Tengvall

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

Original languageEnglish
Pages (from-to)7064-7073
Number of pages10
JournalActa Biomaterialia
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 2013
Externally publishedYes

Fingerprint

Alendronate
Titanium oxides
Oxide films
Bone
Bone and Bones
Osteoporosis
Drug Implants
Quartz Crystal Microbalance Techniques
Pharmaceutical Preparations
Apatites
Bone Remodeling
Coatings
Torque
Tibia
Bone Density
Oxides
Pharmacokinetics
Quartz crystal microbalances
Polymerase chain reaction
Apatite

Keywords

  • Bisphosphonate
  • Drug delivery
  • Mesoporous
  • Raloxifene
  • Titanium

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

Harmankaya, N., Karlsson, J., Palmquist, A., Halvarsson, M., Igawa, K., Andersson, M., & Tengvall, P. (2013). Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone. Acta Biomaterialia, 9(6), 7064-7073. https://doi.org/10.1016/j.actbio.2013.02.040

Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone. / Harmankaya, N.; Karlsson, J.; Palmquist, A.; Halvarsson, M.; Igawa, Kazuyo; Andersson, M.; Tengvall, P.

In: Acta Biomaterialia, Vol. 9, No. 6, 06.2013, p. 7064-7073.

Research output: Contribution to journalArticle

Harmankaya, N, Karlsson, J, Palmquist, A, Halvarsson, M, Igawa, K, Andersson, M & Tengvall, P 2013, 'Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone', Acta Biomaterialia, vol. 9, no. 6, pp. 7064-7073. https://doi.org/10.1016/j.actbio.2013.02.040
Harmankaya, N. ; Karlsson, J. ; Palmquist, A. ; Halvarsson, M. ; Igawa, Kazuyo ; Andersson, M. ; Tengvall, P. / Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone. In: Acta Biomaterialia. 2013 ; Vol. 9, No. 6. pp. 7064-7073.
@article{a7be138ff19c4e169bd4ce74ff33315c,
title = "Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone",
abstract = "This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.",
keywords = "Bisphosphonate, Drug delivery, Mesoporous, Raloxifene, Titanium",
author = "N. Harmankaya and J. Karlsson and A. Palmquist and M. Halvarsson and Kazuyo Igawa and M. Andersson and P. Tengvall",
year = "2013",
month = "6",
doi = "10.1016/j.actbio.2013.02.040",
language = "English",
volume = "9",
pages = "7064--7073",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

AU - Harmankaya, N.

AU - Karlsson, J.

AU - Palmquist, A.

AU - Halvarsson, M.

AU - Igawa, Kazuyo

AU - Andersson, M.

AU - Tengvall, P.

PY - 2013/6

Y1 - 2013/6

N2 - This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

AB - This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

KW - Bisphosphonate

KW - Drug delivery

KW - Mesoporous

KW - Raloxifene

KW - Titanium

UR - http://www.scopus.com/inward/record.url?scp=84877706313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877706313&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2013.02.040

DO - 10.1016/j.actbio.2013.02.040

M3 - Article

C2 - 23467043

AN - SCOPUS:84877706313

VL - 9

SP - 7064

EP - 7073

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 6

ER -